Partnerships - HiFiBio Therapeutics
Partnering
We believe bringing successful new therapies to patients in IO and I&I diseases requires more than innovation — it takes exceptional partnerships. By combining our expertise with like-minded partners, we work to deliver effective, life-changing medicines to patients worldwide.
Collaborating to Transform Treatments
We seek to collaborate with partners to advance our IO and I&I portfolio of targeted therapies
- Out-license of select pipeline assets from discovery to clinical programs
- Co-development of internal pipeline assets
- Collaborations to explore novel & innovative technologies
- Expansion of our disease cell atlas and translational technologies
Please send any inquiries by email to: bd@hifibio.com
IO Programs Available for Partnership
| Program |
Discovery |
Preclinical (IND) |
Phase I |
Phase II/III |
| Immuno-oncology |
|
|
|
|
| HFB200603* BTLA Antagonist |
|
|
|
|
| Emunkitug* (HFB200301) TNFR2 Agonist |
|
|
|
|
| Nuvustotug (HFB301001) OX40 Agonist |
|
|
|
|
| HFB200902 Gal-9 Antagonist |
|
|
|
|
| HFB101110 CCR8 Depletor |
|
|
|
|
| Immunology & Inflammation |
|
|
|
|
| HFB200604 BTLA Agonist |
|
|
|
|
| HFB100204 CXCR5 Depletor |
|
|
|
|
| HFB3024 KLRG1 Depletor |
|
|
|
|
| HFB2025 PD-1 Depletor |
|
|
|
|
| HFB2027 TNFR2 Agonist |
|
|
|
|
| Bispecifics Novel targets |
|
|
|
|
As monotherapy or in combination with anti-PD-1, Tislelizumab, supply agreement with Novartis
Publications
HFB200301
HFB200603
HFB301001
Other IO Programs
|
|
Sep 25, 2025 |
| HiFiBiO Therapeutics to Present Updated Phase 1 Clinical Data of Two Immuno-Oncology Programs at the 2025 Annual Meeting of the European Society for Medical Oncology (ESMO) |
|
|
| Society for Immunotherapy of Cancer |
|
|
| Poster |
|
|
| Nov 08, 2024 |
|
|
| Predictive and generative AI to guide the clinical development of HFB200301, a first-in-class TNFR2 agonist: Drug Intelligence Science (DIS®) |
|
|
| European Society for Medical Oncology |
|
|
| Poster |
|
|
| Sep 14, 2024 |
|
|
| Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody, in monotherapy and in combination with the anti-PD-1 tislelizumab in patients with advanced solid tumors |
|
|
| American Society of Clinical Oncology |
|
|
| Poster |
|
|
| Jun 01, 2024 |
|
|
| Phase I Dose Escalation Trial of the First-in-Class TNFR2 Agonist Monoclonal Antibody, HFB200301, in Monotherapy and in Combination with Tislelizumab, an Anti-PD-1 Monoclonal Antibody, in adult Patients with Advanced Solid Tumors |
|
|
| American Association for Cancer Research |
|
|
| Poster |
|
|
| Apr 10, 2024 |
|
|
| Optimization of T cell Co-Stimulatory Agonists: A Semi-Mechanistic PKPD Model Integrating Drug Properties and Tumor-Immune Interactions |
|
|
| American Society of Clinical Oncology |
|
|
| Poster |
|
|
| Apr 27, 2022 |
|
|
| Phase I Study of HFB200301, a First-in-Class TNFR2 Agonist Monoclonal Antibody in Patients with Solid Tumors Selected via Drug Intelligent Science (DIS™) |
|
|
| American Association for Cancer Research |
|
|
| Presentation |
|
|
| Apr 12, 2021 |
|
|
| Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer |
|
|
| American Association for Cancer Research |
|
|
| Poster |
|
|
| Jul 03, 2020 |
|
|
| Discovery and Characterization of Novel TNFR2 Antibodies to Modulate T Cell Activities in Immunosuppressive Environment |
|
|
Related News
Apr 16, 2024 HiFiBiO Therapeutics Receives Grant to Research Long COVID and ME/CFS in Collaboration with UMass Chan Medical School
Dec 20, 2021 FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program
Jun 17, 2021 FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease